Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086540 | 0.83 | GRIN2D (0.53) | NR4A1NR4A2NR4A3KDM4EHDAC8 | |
| SCHEMBL3245844 | 0.82 | CYP1A2 (0.54) | NR4A1NR4A2NR4A3KDM4EHDAC8 | |
| SCHEMBL3245346 | 0.82 | MTNR1A (0.57) | NR4A1NR4A2NR4A3KDM4EHDAC8 | |
| SCHEMBL29470165 | 0.80 | HDAC8 (0.67) | KDM4EHDAC8HDAC6MTNR1AMTNR1B | |
| SCHEMBL2903467 | 0.80 | HDAC8 (0.67) | KDM4EHDAC8HDAC6MTNR1AMTNR1B | |
| SCHEMBL79668 | 0.80 | HDAC8 (0.67) | KDM4EHDAC8HDAC6MTNR1AMTNR1B | |
| SCHEMBL29404405 | 0.80 | HDAC8 (0.67) | KDM4EHDAC8HDAC6MTNR1AMTNR1B | |
| SCHEMBL600540 | 0.80 | HDAC8 (0.67) | KDM4EHDAC8HDAC6MTNR1AMTNR1B | |
| SCHEMBL28312715 | 0.80 | MTNR1A (0.56) | NR4A1NR4A2NR4A3KDM4EHDAC8 | |
| Bicarbonate SCHEMBL8390328 | 0.79 | HDAC8 (0.51) | NR4A1NR4A2NR4A3KDM4EHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060257917-A1 | FLUORESCENT DYES, ENERGY TRANSFER COUPLES AND METHODS | MILLIPORE CORPORATION | 2006-11-16 | — | — | US | claimed |
| US-7091348-B2 | Fluorescent dyes, energy transfer couples and methods | GUAVA TECHNOLOGIES, INC. (US) | 2006-08-15 | — | — | US | claimed |
| EP-1539728-A2 | FLUORESCENT DYES, ENERGY TRANSFER COUPLES AND METHODS | Guava Technologies, Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040073014-A1 | Fluorescent dyes, energy transfer couples and methods | EMD MILLIPORE CORPORATION | 2004-04-15 | — | — | US | claimed |
| WO-2004003510-A2 | FLUORESCENT DYES, ENERGY TRANSFER COUPLES AND METHODS | GUAVA TECHNOLOGIES, INC. (US) | 2004-01-08 | — | — | WO | claimed |
| US-20060257917-A1 | FLUORESCENT DYES, ENERGY TRANSFER COUPLES AND METHODS | MILLIPORE CORPORATION | 2006-11-16 | — | — | US | disclosed |
| US-7091348-B2 | Fluorescent dyes, energy transfer couples and methods | GUAVA TECHNOLOGIES, INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1539728-A2 | FLUORESCENT DYES, ENERGY TRANSFER COUPLES AND METHODS | Guava Technologies, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040073014-A1 | Fluorescent dyes, energy transfer couples and methods | EMD MILLIPORE CORPORATION | 2004-04-15 | — | — | US | disclosed |
| WO-2004003510-A2 | FLUORESCENT DYES, ENERGY TRANSFER COUPLES AND METHODS | GUAVA TECHNOLOGIES, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| EP-0179808-B1 | PHARMACEUTICAL COMPOSITION SUITABLE FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-10-30 | — | — | EP | disclosed |
| US-5017609-A | Storage stability, adrenergic blocking agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-05-21 | — | — | US | disclosed |
| WO-1985004580-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1985-10-24 | — | — | WO | disclosed |
| US-4288364-A | REACTING A 3-/2-HYDROXYIMINOACETYLAMINO/-2-OXOAZETIDINE WITH AN ORGANIC CARBONATE OR ACYL HALIDE | CIBA-GEIGY CORPORATION (US) | 1981-09-08 | — | — | US | disclosed |
| EP-0005507-A1 | Process for the fragmentation of 3-(2-hydroxyimino-acetylamino)-2-oxo azetidin compounds and compounds obtained thereby | CIBA-GEIGY AG (CH) | 1979-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060257917-A1 | FLUORESCENT DYES, ENERGY TRANSFER COUPLES AND METHODS | TIMM50, TIMM44, APEX1 | NR4A1 2389/4885NR4A2 2433/4885NR4A3 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.